

# Biosynthesis of two quercetin *O*-diglycosides in *Escherichia coli*

Dae Gyun An<sup>1</sup> · So Mi Yang<sup>1</sup> · Bong Gyu Kim<sup>2</sup> · Joong-Hoon Ahn<sup>1</sup>

Received: 8 December 2015 / Accepted: 15 February 2016 / Published online: 1 March 2016  
© Society for Industrial Microbiology and Biotechnology 2016

**Abstract** Various flavonoid glycosides are found in nature, and their biological activities are as variable as their number. In some cases, the sugar moiety attached to the flavonoid modulates its biological activities. Flavonoid glycones are not easily synthesized chemically. Therefore, in this study, we attempted to synthesize quercetin 3-*O*-glucosyl (1→2) xyloside and quercetin 3-*O*-glucosyl (1→6) rhamnoside (also called rutin) using two uridine diphosphate-dependent glycosyltransferases (UGTs) in *Escherichia coli*. To synthesize quercetin 3-*O*-glucosyl (1→2) xyloside, sequential glycosylation was carried out by regulating the expression time of the two UGTs. AtUGT78D2 was subcloned into a vector controlled by a Tac promoter without a *lacI* operator, while AtUGT79B1 was subcloned into a vector controlled by a T7 promoter. UDP-xyloside was supplied by concomitantly expressing UDP-glucose dehydrogenase (*ugd*) and UDP-xyloside synthase (*UXS*) in the *E. coli*. Using these strategies, 65.0 mg/L of quercetin 3-*O*-glucosyl (1→2) xyloside was produced. For the synthesis of rutin, one UGT (*BcGT1*) was integrated into the *E. coli* chromosome and the other UGT (*Fg2*) was expressed in a plasmid along with *RHM2* (rhamnose synthase gene 2). After optimization of the initial cell concentration and incubation temperature, 119.8 mg/L of rutin was produced. The strategies used in this study thus show promise for the synthesis of flavonoid diglycosides in *E. coli*.

**Keywords** Flavonoid diglycosides · Glycosyltransferase · Metabolic engineering

## Introduction

Many secondary metabolites exist as glycones, and in several instances, the attached sugar moiety modulates their biological activities. In fact, the attachment of diverse sugar moieties to secondary metabolites has been shown to alter their biological activities [9, 28].

Flavonoids are secondary metabolites, and the availability of several hydroxyl groups and glycosyltransferases (GTs) from multiple sources makes them good candidates for studying the attachment of sugar moieties. GTs use nucleotide sugars, mainly uridine diphosphate sugars (UDP-sugars) or thymine diphosphate sugars (TDP-sugars). Most GTs show a preference for UDP-sugar, and these GTs are called uridine diphosphate-dependent GTs (UGTs) [29, 32]. Diverse sugars, including glucose, galactose, arabinose, glucuronic acid, xylose, and rhamnose, can be attached to flavonoids through an ether linkage [1]. The advent of metabolomics, together with whole genome sequencing of model organisms has led to the identification of various flavonoid glycosides, enabling the characterization of GTs with novel nucleotide sugar selectivities. Plants synthesize flavonoid *O*-glycosides and flavonoid *O*-diglycosides. Flavonoid *O*-diglycosides such as quercetin 3-*O*-glucose 7-*O*-rhamnose and kaempferol 3-*O*-glucose 7-*O*-rhamnose were detected in *Arabidopsis thaliana* by a metabolomics approach [30]. AtUGT78D1, which encodes flavonol 3-*O*-rhamnosyltransferase in *A. thaliana*, was characterized through these approaches [8]. Flavonol 3-*O*-arabinosyltransferase (UGT78D3), flavonol 3-*O*-rhamnosyltransferase (UGT78D1), and anthocyanin

✉ Joong-Hoon Ahn  
jhahn@konkuk.ac.kr

<sup>1</sup> Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Seoul 05029, Korea

<sup>2</sup> Department of Forest Resources, Gyeongnam National University of Science and Technology, 33 Dongjin-ro, Jinju-si, Gyeongsangman-do 660-758, Republic of Korea


3-*O*-glucose:2''-*O*-xylosyltransferase (UGT79B1) were also characterized via metabolomics analysis using mutants [8, 30, 31]. Plants also produce flavonoid *O*-glycosyl → glycosides. For example, naringenin 7-*O*-glucose (1→2) rhamnose is responsible for the bitter flavor of citrus [4]. The GTs that generate these flavonoids are a valuable resource for the production of flavonoid glycosides in heterologous systems such as *Escherichia coli* and *Saccharomyces cerevisiae*.

Biotransformation of flavonoids using *E. coli* expressing UGTs has been previously attempted, giving rise to flavonoid *O*-glucoside as the primary reaction product [16]. Strategies to synthesize flavonoid glycones other than flavonoid glucosides have also been developed (reviewed by Kim et al. [16]). The synthesis of other flavonoid glycosides in *E. coli* requires the engineering of both nucleotide sugar biosynthesis in *E. coli* and UGTs, which recognize a novel nucleotide sugar as well as flavonoids. Using these approaches, a range of naturally occurring flavonoid *O*-glycosides including flavonoid *O*-galactoside, flavonoid *O*-glucuronide, flavonoid *O*-rhamnoside, flavonoid *O*-xyloside, and flavonoid *O*-arabinoside have been synthesized [6, 17, 18, 23, 27]. In addition, novel flavonoid glycosides not found in nature have also been synthesized [12, 15, 27, 33]. However, despite their biological activities including anti-inflammatory, antioxidant, and antibacterial activities as well as their established role in the inhibition of platelet aggregation and blood vessel protection [5, 20, 21, 25], the synthesis of flavonoid *O*-diglycosides in *E. coli* has not been previously attempted. In the present study, we report the biosynthesis of quercetin 3-*O*-glucosyl (1→2) xyloside and quercetin 3-*O*-glucosyl (1→6) rhamnoside in *E. coli* by engineering the nucleotide pathway and introducing two UGTs either from *A. thaliana* (*AtUGT78D1* and *AtUGT79B1*) for the synthesis of quercetin 3-*O*-glucosyl (1→2) xyloside, or from *Bacillus subtilis* (*BcGT1*) and from *Glycine max* (*Fg2*) for the synthesis of quercetin 3-*O*-glucosyl (1→6) rhamnoside).

## Materials and methods

### Constructs

The pTac-pCDFDuet vector was derived from pCDFDuet (Novagen) (Fig. 1). Two primers were designed to eliminate the *lacI* gene from pCDFDuet and insert a *tac* promoter [3]. The forward primer contains the *tac* promoter (shown in uppercase), ribosome binding sequence (underlined), and a pCDFDuet-specific sequence (nucleotides 106 to 125, shown in lowercase) 5'-TGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGag-gaggattacaagatccgaattcagctcgg-3'. The reverse primer



**Fig. 1** Diagram of the pTac-PCDF vector

is located from nucleotides 2589 to 2561 in pCDFDuet and its sequence is 5'-GACAGGTTTCCCGACTGGAAAGCGGGCAG-3'. PCR was carried out with the two primers listed above, the pCDFDuet vector, as template and Pyrobest Taq polymerase (Takara, Japan). The PCR products were purified using the Gel Extraction Kit (Bioneer, Korea) and ligated. *AtUGT78D2* from *A. thaliana*, which was cloned previously [15], was cloned into the EcoRI/NotI site of pCDFDuet and pTac-pCDFDuet (Fig. 1) and the resulting plasmids were called pC-UGTD2 and pTac-pC-UGTD2, respectively. *AtUGT79B1* (At5g54060) [30] was cloned using reverse-transcription polymerase chain reaction (RT-PCR), as described previously [15]. Two primers containing an EcoRI site and a NotI site (lower case letters in the primer sequence), respectively, 5'-AAGaattcaATGGGTGTTTTTGGATCGAATGA-3' and 5'-aagcggccgcTCATGACTTCACAAGTTCAATT-3' were used. The resulting PCR product was digested with EcoRI and NotI and subcloned into the EcoRI/NotI site of the *E. coli* expression vector pGEX 5X-3, and the resulting plasmid was called pG-UGTB1. *UXS* from *A. thaliana* (*AtUXS*) and *ugd* (UDP-glucose dehydrogenase) from *E. coli* (*Ecugd*) were previously cloned [6] and were subcloned into the EcoRI/NotI site and NdeI/XhoI sites of the pACYCDuet vector, respectively. The resulting construct was called pA-*AtUXS*-*Ecugd*. *E. coli* strains, BarnA and Bpgi, in which *arnA* (UDP-L-Ara4N formyltransferase/UDP-GlcA C-4''-decarboxylase) and *pgi* (phosphoglucosomerase) were deleted, respectively, were generated as described by Kim et al. [12, 15].

*AtUGT78D2* [5], *BcGT1* [19], and *RHM* [14] were cloned previously.

To synthesize rutin, the *BcGT1* gene from *B. subtilis* was integrated into the *tyrR* (tyrosine DNA-binding transcriptional repressor) gene of *E. coli*. *BcGT1* was subcloned into the pACYCDuet vector, and the resulting construct was used as a template for PCR. The primers used were 5'-GTGTCATATCATCAT-ATTAATTGTTCTTTTTTCAGGTGAAGGTTCC-CATGGCTATCATGCCATACCGCGA-3' as a forward

primer and 5'-TTGCACCATCAGGCATATTCGCGC  
TTACTCTTCGTTCTTCTTCTGACTCACTGATGTCC  
GGCGGTGCTTT-3' as a reverse primer (the *E. coli tyrR*  
sequences are underlined and the other sequences are that  
of the pACYCDuet vector).

UGT from *G. max* (*Fg2*, GenBank accession number  
NM\_001288595) [24] was cloned using RT-PCR. RNA was  
isolated from the leaves of *G. max* using the Plant Total  
RNA Isolation Kit (Qiagen), and cDNA was synthesized with  
Omniscript reverse transcriptase (Qiagen) using oligo dT  
primer. The primers used to clone *Fg2* were 5'-AAGAATTC  
AATGCCTAGTGAATTAGC  
TATGAA-3' (EcoRI site underlined.) as a forward  
primer and 5'-AAGCGGCCGGCTAAGCCATAGACTT  
TAAGTGGG-3' (NotI site underlined.) as a reverse  
primer. The PCR product was subcloned into the EcoRI/  
NotI site of pGEX 5X-3. *Cs1,6RhaT* from *Citrus sinensis*  
(GenBank accession number DQ119035) was cloned using  
RT-PCR. Primers 5'-AAGAATTCAATGCACGCC  
CTTCGA-3' (with EcoRI site underlined.) as a forward  
primer 5'-AAGCGGCCGGCTTAAGCTAAGGCTTTGAG  
ATCC-3' (NotI site is underlined) as a reverse primer.

### Biotransformation of quercetin

To compare the production of quercetin 3-*O*-glucosyl  
(1→2) xyloside in the *E. coli* strains and to optimize the  
cell concentration, *E. coli* cells were grown in 2 mL of  
LB medium containing 50 µg/ml of antibiotics at 37 °C  
for 18 h. The cultured cells were inoculated into fresh LB  
medium containing antibiotics, and the cells were grown  
until the OD<sub>600</sub> reached 1.0. The cells were collected by  
centrifugation, and the cell concentration was adjusted to  
an OD<sub>600</sub> of 1.0 with 2 mL of M9 medium supplemented  
with 1 % yeast extract, 2 % glucose, and 50 µg/mL anti-  
biotics. Quercetin (200 µM; dissolved in dimethyl sul-  
foxide [DMSO]) was also added, and the culture was  
incubated at 30 °C with shaking for 6 h. Isopropyl β-D-1-  
thiogalactopyranoside (IPTG) was added to the culture at a  
final concentration of 1 mM, and the culture was incubated  
for 20 h at 30 °C. The culture supernatant, which contained  
most of the product, was boiled for 3 min and centrifuged  
for 15 min. The supernatant was analyzed by HPLC.

Rutin was produced in *E. coli* strains BGR-1, BGR-2,  
and BGR-3. An overnight culture of *E. coli* was inoculated  
into 3 mL of a fresh LB medium containing 50 µg/mL anti-  
biotics. The cells were grown until the OD<sub>600</sub> reached 0.8,  
and then IPTG was added to a final concentration of 1 mM.  
The culture was incubated at 18 °C for 18 h with shaking  
at 180 rpm. The cells were harvested via centrifugation and  
resuspended with an OD<sub>600</sub> of 3.0 in M9 medium contain-  
ing 2 % glucose, 1 mM IPTG, 50 µg/mL antibiotics, and  
50 µM quercetin. This culture was incubated at 30 °C.

To measure the conversion of quercetin into rutin using  
strain BGR-3, 50 µM quercetin was added to the culture  
at 0, 8, 17, and 26 h (for a final concentration of 200 µM).  
Samples were harvested at 4, 6, 8, 14, 17, 24, 26, 34, and  
48 h and were boiled for 5 min. After centrifugation, the  
supernatant (100 µL) was analyzed by HPLC.

### HPLC analysis of reaction products

The reaction products were analyzed using a Thermo Ulti-  
mate 3000 HPLC equipped with a photo diode array (PDA)  
detector and a C18 reversed-phase column (4.60 × 250 mm,  
3.5 µm particle size, Varian). For the analysis, the mobile  
phase consisted of H<sub>2</sub>O containing 0.1 % formic acid (pH  
3.0) with the following gradient: 40 % acetonitrile for  
8 min, 90 % acetonitrile for 12 min, 90 % acetonitrile for  
15 min, and 10 % acetonitrile for 20 min. The flow rate was  
1 mL/min and UV detection was dually performed at 290  
and 340 nm. The UV spectrum at 340 nm was used. Authen-  
tic rutin was used to calculation of the amount of quercetin  
3-*O*-glucosyl (1→2) xyloside and quercetin 3-*O*-glucosyl  
(1→6) rhamnoside because only rutin was commercially  
available. The means and standard errors were calculated  
from triplicate experiments. Analysis of variance (ANOVA)  
was carried out using Tukey's method with a significance  
level of 1 % in Excel 2010 (Microsoft).

To determine the structure of the reaction products, the  
culture supernatant was concentrated using a non-polar  
copolymer styrene–divinylbenzene adsorbent resin (HP-  
20, Samyang, Korea). The reaction product was eluted with  
methanol, and was then evaporated to dryness. The sample  
was dissolved again in a small amount of methanol and  
purified by HPLC. The structure of the reaction product  
was determined using nuclear magnetic resonance (NMR)  
spectroscopy [33].

The <sup>13</sup>C NMR spectrum of the reaction product from the  
BGX-3 matched that of the known compound, quercetin  
3-*O*-xylosyl (1''→2'') glucoside [26]: <sup>13</sup>C NMR (100 MHz,  
DMSO-*d*<sub>6</sub>) δ ppm 177.4 (C-4), 164.1 (C-7), 161.2 (C-5),  
156.2 (C-9), 155.3 (C-2), 148.5 (C-4'), 144.9 (C-3'), 132.9  
(C-3), 121.9 (C-6'), 121.2 (C-1'), 115.9 (C-5'), 115.2  
(C-2'), 104.5 (C-1'''), 103.8 (C-10), 98.6 (C-6), 97.9 (C-1''),  
93.4 (C-8), 81.8 (C-2''), 77.6 (C-5'''), 76.8 (C-3''), 76.1  
(C-3'''), 73.9 (C-2'''), 69.5 (C-4'''), 69.4 (C-4'''), 65.6 (C-5'''),  
60.6 (C-6''); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ ppm 7.66  
(dd, *J* = 8.5, 2.2 Hz, 1H, H-6'), 7.56 (d, *J* = 2.2 Hz, 1H,  
H-2'), 6.85 (d, *J* = 8.5 Hz, 1H, H-5'), 6.40 (br s, 1H, H-8),  
6.19 (br s, 1H, H-6), 5.72 (d, *J* = 7.2 Hz, 1H, H-1''), 4.59  
(d, *J* = 7.3 Hz, 1H, H-1'''), 3.68 (dd, *J* = 11.2, 5.0 Hz, 1H,  
H-5''<sub>A</sub>), 3.55 (d, *J* = 11.2 Hz, 1H, H-6''<sub>A</sub>), 3.51 ~ 3.45 (m,  
2H, H-2'' and H-4'''), 3.33–3.24 (m, 2H, H-6''<sub>B</sub> and H-3'''),  
3.16–3.10 (m, 3H, H-4'', H-5'' and H-3'''), 3.07–3.04 (m,  
2H, H-2''' and H-5''').

The proton NMR spectrum of the reaction product of strain BGR-2 matched that of rutin [10].  $^1\text{H}$  NMR (MeOH, 400 MHz)  $\delta$  (ppm) 7.69 (1H, d, 2.1 Hz), 7.64 (1H, dd, 2.1, 8.5 Hz), 6.89 (1H, d, 8.5 Hz), 6.41 (1H, d, 2.0 Hz), 6.22(1H, d, 2.0 Hz), 5.11 (1H, d, 7.6 Hz), 4.53 (1H, d, 1.7 Hz), 3.82(1H, dd, 1.2, 11.0 Hz), 3.64(1H, dd, 1.7, 3.4 Hz), 3.55(1H, dd, 3.4, 9.5 Hz), 3.38–3.50(4H, m), 3.24–3.30(2H, m), 1.13(3H, d, 6.2 Hz).

## Results

### Synthesis of quercetin 3-*O*-glucosyl (1→2) xyloside in *E. coli*

*E. coli* synthesizes UDP-glucose but does not synthesize UDP-xylose. UDP-xylose is synthesized from UDP-glucuronic acid by the action of UDP-xylose synthase (UXS). UXS has been previously characterized in *A. thaliana* [7]. To synthesize UDP-xyloside in *E. coli*, two genes, UDP-glucose dehydrogenase (*ugd*) from *E. coli*, which converts UDP-glucose to UDP-glucuronic acid, and UXS were overexpressed. Overexpression of *ugd* was expected to provide more UDP-glucuronic acid, the direct substrate of UXS. One UGT from *A. thaliana*, AtUGT78D2, uses quercetin as a sugar acceptor and UDP-glucose as a sugar donor to make quercetin 3-*O*-glucoside [22]. Another UGT from *A. thaliana*, AtUGT79B1, uses quercetin 3-*O*-glucoside as a sugar acceptor and UDP-xyloside as a sugar donor to synthesize quercetin 3-*O*-glucosyl (1→2) xyloside. To synthesize quercetin 3-*O*-glucoside (1→2) xyloside from quercetin, quercetin 3-*O*-glucoside needs to be synthesized before the reaction catalyzed by AtUGT79B1 can occur. Although AtUGT79B1 used quercetin 3-*O*-glucoside as a sugar acceptor and UDP-xyloside as a sugar donor, it could use quercetin as a sugar acceptor and make quercetin 3-*O*-xyloside (described below). Therefore, sequential glycosylation of quercetin was necessary to minimize byproduct production and maximize the production of quercetin 3-*O*-glucoside (1→2) xyloside. As a strategy to promote sequential glycosylation, we used two different promoters to express AtUGT78D2 and AtUGT79B1. AtUGT78D2 was cloned into pTac-pCDFduet and the resulting construct was named pTac-pC-D2. This construct contained a tac promoter instead of a T7 promoter without a lac operator; therefore, the expression of AtUGT78D2 was constitutive. As a control, AtUGT78D2 was also subcloned into pCDFduet to generate pC-D2, which is controlled by a T7 promoter. AtUGT79B1 was subcloned into pGEX5X-2 to generate pG-B1, which has a lac operator and tac promoter [3]. AtUXS, and *Ecugd* were subcloned into pACYCDuet vector to generate pA-AtUXS-*Ecugd* in which expression is controlled by T7 promoter. Their expression was induced by the addition of IPTG. Three

constructs, pC-D2, pG-C1, and pA-AtUXS-*Ecugd* were transformed into an *E. coli* *arnA* deletion mutant (BarnA in Table 1). ArnA competes with UXS for UDP-glucuronic acid [2]. Deletion of *araA* should provide more UDP-glucuronic acid to UXS for the biosynthesis of UDP-xyloside. Our previous study also showed that this BarnA strain produced more UDP-xyloside than the wild-type BL21 (DE3) strain [6]. The resulting transformant was named BGX-1. pTac-pC-D2, pG-C1, and pA-AtUXS-*Ecugd* were also transformed together into BarnA and the resulting strain was called BGX-2. These two *E. coli* strains, BGX-1 and BGX-2, were used for the biotransformation of quercetin. The resulting product was analyzed by HPLC (Fig. 2). BGX-1 showed four peaks while BGX-2 showed two peaks. Based on a comparison of the HPLC retention time with the standard molecules, P2, P3, and P4 were determined to be quercetin 3-*O*-glucoside, quercetin 3-*O*-xyloside, and quercetin 3-*O*-*N*-acetylglucosamine, respectively (data not shown). The structure of reaction product (P1) from BGX-2 was determined to be quercetin 3-*O*-xylosyl (1'''→2'') glucoside by NMR.

BGX-1 accumulated more quercetin 3-*O*-glucoside (33 mg/L) than quercetin 3-*O*-glucoside (1→2) xyloside (8 mg/L) while BGX-2 produced more quercetin 3-*O*-glucoside (1→2) xyloside (35 mg/L) than quercetin 3-*O*-glucoside (27 mg/L) (Fig. 3). BXG-1 showed the presence of similar amounts of quercetin 3-*O*-glucoside even after longer incubation without converting into quercetin 3-*O*-glucoside (1→2) xyloside. These results showed that the sequential expression of UGT is critical for the production of quercetin 3-*O*-glucoside (1→2) xyloside.

We optimized the initial cell concentration for the production of quercetin 3-*O*-glucoside (1→2) xyloside using strain BGX-2. The optimum cell concentration was determined by varying the initial cell density ( $\text{OD}_{600} = 1-5$ ). The production of quercetin 3-*O*-glucoside (1→2) xyloside was the highest at an  $\text{OD}_{600}$  of 3 (55 mg/L). The conversion of quercetin to quercetin 3-*O*-glucoside (1→2) xyloside was monitored over time at the optimal initial BXG-2 cell concentration. After incubation of BGX-2 cells with quercetin for 6 h, 85 % of the quercetin was converted to quercetin 3-*O*-glucoside. The addition of IPTG induced the expression of the enzymes required for the biosynthesis of quercetin 3-*O*-glucoside (1→2) xyloside from quercetin 3-*O*-glucoside, resulting in the conversion of approximately 50 % of the synthesized quercetin 3-*O*-glucoside into quercetin 3-*O*-glucoside (1→2) xyloside within 2 h. After 2 h, the conversion rate of quercetin 3-*O*-glucoside or quercetin 3-*O*-glucoside (1→2) xyloside was reduced (Fig. 4). At 24 h, 65 mg/L quercetin 3-*O*-glucoside (1→2) xyloside was produced, while approximately 40 mg/L quercetin 3-*O*-glucoside was still present. Thus, approximately 54.5 % of the quercetin was converted into quercetin 3-*O*-glucoside (1→2) xyloside.

**Table 1** Plasmids and strains used in the present study


Plasmids or <i>E. coli</i> strain	Relevant properties or genetic marker	Source or reference
<b>Plasmids</b>		
pCDFDuet	CloDE13 ori, spectinomycin resistance (Str <sup>r</sup> )	Novagen
pACYCDuet	P15a ORI, chloramphenicol resistance	Novagen
pTac-pCDFDuet	CloDE13 ori, Str <sup>r</sup> , ΔlacI, the T7 promoter in the multiple cloning site I was replaced by pTac promoter	This study
pGEX 5X-2	pRR322 ori, ampicillin resistance	GE Healthcare
pC-D2	pCDFDuet + <i>AtUGT78D2</i> from <i>Arabidopsis thaliana</i>	This study
pA-D2	pACYCDuet + <i>AtUGT78D2</i> from <i>Arabidopsis thaliana</i>	This study
pA-BcGT1	pACYCDuet + <i>BcGT1</i> from <i>Bacillus subtilis</i>	This study
pTac-pC-D2	pTac-pCDFDuet + <i>AtUGT78D2</i> from <i>A. thaliana</i>	This study
pG-B1	pGEX 5X-2 + <i>AtUGT79B1</i> from <i>A. thaliana</i>	This study
pA-AtUXS-Ecugd	pACYCDuet + <i>AtUXS</i> from <i>A. thaliana</i> + <i>ugd</i> from <i>E. coli</i>	Han et al. [6]
pG-Fg2	pGEX 5X-3 + <i>UGT</i> from <i>Glycine max</i> ( <i>Fg2</i> )	This study
<b>Strains</b>		
BL21 (DE3)	F <sup>-</sup> <i>ompT hsdS<sub>B</sub>(r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm lon</i> (DE3)	
BarnA	BL21(DE3) Δ <i>arnA</i>	Kim et al. [11]
B-BcGT1	BL21 (DE3) integrating <i>BcGT1</i> into <i>tyrR</i> of <i>E. coli</i>	This study
BGX-1	BL21(DE3) harboring pC-D2, pG-B1, and pA-AtUXS-Ecugd	This study
BGX-2	BL21(DE3) harboring pTac-pC-D2, pG-B1, and pA-AtUXS-Ecugd	This study
BGR-1	BL21(DE3) harboring pA-D2, pC-RHM, and pG-Fg2	This study
BGR-2	BL21(DE3) harboring pA-BcGT1, pC-RHM, and pG-Fg2	This study
BGR-3	B-BcGT harboring pC-RHM, and pG-Fg2	This study

### Synthesis of quercetin 3-*O*-glucosyl (1→6) rhamnoside (rutin) in *E. coli*

Two UGTs, *Fg2* from *G. max* and *Cm1,6RhaT* from *C. sinensis*, were implicated in the conversion of quercetin 3-*O*-glucoside to rutin [4, 24]. We evaluated the ability of *Fg2* and *Cm1,6RhaT* to synthesize rutin from quercetin 3-*O*-glucoside in *E. coli*. Each gene, along with *RHM2* encoding UDP-rhamnose synthase was transformed into *E. coli*, and each resulting transformant was tested for its ability to synthesize rutin from quercetin 3-*O*-glucoside. Analysis of culture filtrates from both transformants showed a peak with the same retention time as that of the rutin standard. In addition, the molecular mass of the product was 609.7 Da, which corresponded with the predicted molecular mass of rutin (data not shown). The structure of the reaction product was determined to be rutin using NMR (See “Materials and methods”). An *E. coli* harboring *Fg2* and *RHM2* (25.3 mg/L) produced more rutin than an *E. coli* harboring *Cm1,6RhaT* and *RHM2* (22.6 mg/L). Therefore, we decided to use *Fg2* for further analysis.


We attempted to synthesize rutin from quercetin. This required two reactions: the conversion of quercetin to quercetin 3-*O*-glucoside catalyzed by *AtUGT78D2* or *BcGT1* [8, 19] and the conversion of quercetin 3-*O*-glucoside to rutin by *Fg2* and *RHM2*. For this purpose, we

constructed an *E. coli* strain, BGR-1, harboring three genes, *AtUGT78D2*, *Fg2*, and *RHM2*. BGR-1 cells converted quercetin into quercetin 3-*O*-glucoside and rutin. However, even after a longer incubation, only the amount of quercetin 3-*O*-glucoside increased. It is likely that the first reaction (the conversion of quercetin to quercetin 3-*O*-glucoside) is much faster than the second reaction (the conversion of quercetin 3-*O*-glucoside to rutin), and the accumulation of quercetin 3-*O*-glucoside seems to inhibit the second reaction. Usage of pTac-pC-D2 for the biosynthesis of quercetin 3-*O*-glucoside was unsuccessful. The above results suggested that slow synthesis of quercetin 3-*O*-glucoside may increase the yield of rutin. Thus, we decided to lower the copy number of the gene encoding the protein responsible for the conversion of quercetin into quercetin 3-*O*-glucoside. We integrated *BcGT1*, which also converts quercetin into quercetin 3-*O*-glucoside, into the chromosome of *E. coli*. *BcGT1* makes quercetin 3-*O*-glucoside at a slower pace than *AtUGT78D2* (see below). Quercetin was added to a reaction with resulting strain BGR-3, and the culture filtrate was analyzed. As shown in Fig. 5, most of quercetin was converted into rutin, and only a small amount of quercetin 3-*O*-glucoside remained. This indicated that the conversion of quercetin 3-*O*-glucose to rutin should be faster than the conversion of quercetin to quercetin 3-*O*-glucose. To confirm that the copy number of *BcGT1* was related to the




**Fig. 2** Analysis of the quercetin biotransformation products produced by *E. coli* strain BGX-1 (A) or BGX-2 (B). P1 quercetin 3-*O*-glucose (1→2) xylose; P2 quercetin 3-*O*-glucose; P3 quercetin 3-*O*-xylose; P4 quercetin 3-*N*-acetyl glucosamine; substrate, quercetin. Each cell suspension was inoculated into 2 mL of M9 medium supplemented with 1 % yeast extract, 2 % glucose, 50 μg/mL antibiotics and 200 μM quercetin at an OD<sub>600</sub> of 1.0. The cul-

ture was incubated at 30 °C with shaking for 6 h. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture at a final concentration of 1 mM, and the culture was further incubated for 20 h at 30 °C. The culture was harvested, boiled for 3 min and then centrifuged for 15 min. The supernatant was analyzed at 340 nm using HPLC




**Fig. 3** Production of quercetin 3-*O*-glucose (1→2) xylose in different *E. coli* strains. Authentic rutin was used as a standard to determine the production of quercetin 3-*O*-glucosyl (1→2) xyloside because rutin is commercially available. The means and standard errors were calculated from triplicate experiments



**Fig. 4** Production of quercetin 3-*O*-glucose (1→2) xylose using *E. coli* strain BGX-2. The cell density was adjusted to OD<sub>600</sub> of 5.0 with 10 mL of M9 containing 1 % yeast extract, 2 % glucose, 50 μg/mL antibiotics and 200 μM quercetin. The culture was incubated at 30 °C for 6 h, and then IPTG was added at the final concentration of 1 mM. Samples were harvested at 2, 4, 6, 8, 10, 12, and 24 h, and analyzed by HPLC

**Fig. 5** Synthesis of rutin from quercetin using strain BGR-3. **a** Standard rutin; **b** standard quercetin; **c** standard quercetin 3-*O*-glucoside; **d** reaction products of BGR-2 (P1 and P2 are reaction products). An overnight culture of *E. coli* was inoculated in 3 mL of a fresh LB medium containing 50  $\mu\text{g}/\text{mL}$  antibiotics. The cells were grown until the  $\text{OD}_{600}$  reached 0.8 and IPTG was added to the culture at a final concentration of 1 mM. The culture was incubated at 18  $^{\circ}\text{C}$  for 18 h with shaking at 180 rpm. The cells were harvested via centrifugation and resuspended to an  $\text{OD}_{600}$  of 3.0 with M9 medium containing 2 % glucose, 1 mM IPTG, 50  $\mu\text{g}/\text{mL}$  antibiotics, and 50  $\mu\text{M}$  quercetin. The reaction mixture was incubated at 30  $^{\circ}\text{C}$




production of rutin, we compared rutin production between strains BGR-2 and BGR-3. The BGR-3 strain contains one copy of *BcGT1* because it is integrated into the *E. coli* chromosome, whereas the BGR-2 strain contains 10–12 copies of *BcGT1* because *BcGT1* is present on the low copy number plasmid pACYCDuet. The BGR-3 strain produced approximately 25.3 mg/L of rutin, whereas the BGR-1 and BGR-2 strains produced 7.3 and 2.3 mg/L of rutin, respectively, after 7 h. This result supported the observation that the slow production of quercetin 3-*O*-glucoside is critical to maximize the final product yield.

The production of rutin was then further optimized using strain BGR-3. First, the effect of initial cell density was tested. The cell concentration was adjusted to  $\text{OD}_{600}$  values of 0.5, 1.0, 2.0, 3.0, and 4.0 after induction, and the conversion of quercetin to rutin was assessed. The production of rutin continued to increase from an  $\text{OD}_{600}$  of 0.5 (14.0 mg/L) to an  $\text{OD}_{600}$  of 3.0 (25.3 mg/L), but decreased at an  $\text{OD}_{600}$  of 4.0 (19.6 mg/L). Therefore, the optimal initial cell concentration was  $\text{OD}_{600}$  of 3.0. Using the optimized cell concentration of BGR-3, rutin was produced.

Quercetin (50  $\mu\text{M}$ ) was added at 0, 8, 17, and 26 h (a total concentration of 200  $\mu\text{M}$  quercetin was added). The reaction product was periodically sampled and analyzed by HPLC. Approximately 119.8 mg of rutin was obtained after 48 h (Fig. 6) and approximately 98 % of quercetin was converted to rutin.

## Discussion

In the present study, we synthesized two quercetin diglycosides: quercetin 3-*O*-glucose (1 $\rightarrow$ 2) xyloside, and rutin, in *E. coli*. Each quercetin diglycoside was synthesized via a sequential glycosylation reaction using two UGTs. Although the first glycosylation reaction product for both quercetin diglycosides was quercetin 3-*O*-glucoside, two different strategies were employed for its synthesis. For the synthesis quercetin 3-*O*-glucoside (1 $\rightarrow$ 2) xyloside, a constitutive promoter was used; whereas, for the synthesis of rutin, the copy number of the UGT was varied. The strategy for the first reaction was varied based on the enzyme that



**Fig. 6** Production of rutin using *E. coli* strain BGR-2. To measure the conversion of quercetin into rutin using strain BGR-3, 50  $\mu$ M quercetin was added to the culture at 0, 8, 17, and 26 h for a final concentration of 200  $\mu$ M. Samples were harvested at 4, 6, 8, 14, 17, 24, 26, 34, and 48 h and analyzed by HPLC

catalyzed the second reaction. In cases where the conversion of the substrate using the *E. coli* expressing the second UGT is faster, a constitutive promoter could be used; whereas, in cases of low conversion rate of the substrate using the *E. coli* expressing the second UGT, a lower copy number of the first gene proved to be a better choice.

Although rutin is commercially available, most of it is derived from plants, as most natural compounds are generally obtained via extraction and purification from plants sources. However, these methods have a disadvantage owing to the complexity of the refining process. To overcome this, the production of molecules such as rutin using *E. coli* might be a useful alternative. Various quercetin derivatives have been synthesized using *E. coli* expressing different genes [13, 16]; however, the low solubility and antibacterial activity of quercetin have limited the final yield. Here, we showed that sequential additional of quercetin to the culture medium could circumvent this problem. In addition, determination of the initial concentration of quercetin and the feeding time as well as controlling the expression of the biosynthetic genes are important for increasing the final product yield without causing cell lysis and a high metabolic load.

Many bioactive flavonoids are modified by *O*-methylation, glycosylation, and hydroxylation. For example, isorhamnetin 3-*O*-glucoside, which is known to have an effect on diabetic complications [21], is synthesized by sequential 3'-*O*-methylation and 3-*O*-glucosylation of quercetin. The 3'-*O*-methylation of quercetin should occur before the 3-*O*-glucosylation, as quercetin 3-*O*-glucoside does not fit into the substrate binding site of quercetin 3'-*O*-methyltransferase [11]. The strategies used in this study provide a method for the synthesis of bioactive flavonoids using a single strain of *E. coli*.

**Acknowledgments** This work was supported by a Grant from the Next-Generation BioGreen 21 Program (PJ00948301), the Rural Development Administration, and the Priority Research Centers Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2009-0093824).

## References

- Bowles D, Lim E-K, Poppenberger B, Vaistij FE (2006) Glycosyltransferases of lipophilic small molecules. *Annu Rev Plant Biol* 57:567–597. doi:10.1146/annurev.arplant.57.032905.105429
- Breazeale SD, Ribeiro AA, McClerren AL, Raetz CRH (2005) A formyltransferase required for polymyxin resistance in *Escherichia coli* and the modification of lipid A with 4-amino-4-deoxy-L-arabinose. Identification and function of UDP-4-deoxy-4-formamido-L-arabinose. *J Biol Chem* 280(14):14154–14167. doi:10.1074/jbc.M414265200
- De Boer HA, Comstock LJ, Vasser M (1983) The *tac* promoter: a functional hybrid derived from the *trp* and *lac* promoters. *Proc Natl Acad Sci* 80(1):21–25. doi:10.1073/pnas.80.1.21
- Frydman A, Weissshaus O, Bar-Peled M, Huhman DV, Sumner LW, Marin FR, Lewinsohn E, Fluhr R, Gressel J, Eyal Y (2004) Citrus fruit bitter flavors: isolation and functional characterization of the gene *Cm1,2RhaT* encoding a 1,2 rhamnosyltransferase, a key enzyme in the biosynthesis of the bitter flavonoids of citrus. *Plant J* 40(1):88–100. doi:10.1111/j.1365-313X.2004.02193.x
- Guardia T, Rotelli AE, Juarez AO, Pelzer LE (2001) Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. *Farmacologia* 56(9):683–687. doi:10.1016/S0014-827X(01)01111-9
- Han SH, Kim B-G, Yoon JA, Chong Y, Ahn J-H (2014) Synthesis of flavonoid *O*-pentosides by *Escherichia coli* through engineering nucleotide sugar synthesis pathway and glycosyltransferase. *Appl Environ Microbiol* 80(9):2754–2762. doi:10.1128/AEM.03797-13
- Harper AD, Bar-Peled M (2002) Biosynthesis of UDP-xylose. Cloning and characterization of a novel *Arabidopsis* gene family, *UXS*, encoding soluble and putative membrane-bound UDP-glucuronic acid decarboxylase isoforms. *Plant Physiol* 130(4):2188–2198. doi:10.1104/pp.009654
- Jones P, Messner B, Nakajima J-I, Schäffner AR, Saito K (2003) UGT73C6 and UGT78D1, glycosyltransferase involved in flavonol glycoside biosynthesis in *Arabidopsis thaliana*. *J Biol Chem* 278(45):43910–43918. doi:10.1074/jbc.M303523200
- Jürgenliemk G, Boje K, Huwel S, Lohmann C, Galla HJ, Nahrstedt A (2003) In vitro studies indicate that miquelianin (quercetin 3-*O*-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. *Planta Med* 69(11):1013–1017. doi:10.1055/s-2003-45148
- Kazuma K, Noda N, Suzuki M (2003) Malonylated flavonol glycosides from the petals of *Clitoria ternatea*. *Phytochemistry* 62(2):229–237. doi:10.1016/S0031-9422(02)00486-7
- Kim B-G, Sung SH, Jung NR, Chong Y, Ahn J-H (2010) Biological synthesis of isorhamnetin 3-*O*-glucoside using engineered glycosyltransferase. *J Mol Catalysis B: Enzymatic* 63(3–4):194–199. doi:10.1016/j.molcatb.2010.01.012
- Kim B-G, Jung NR, Joe EJ, Hur H-G, Lim Y, Chong Y, Ahn J-H (2010) Bacterial synthesis of a flavonoid deoxyaminosugar conjugate in *Escherichia coli* expressing a glycosyltransferase of *Arabidopsis thaliana*. *ChemBioChem* 11(17):2389–2392. doi:10.1002/cbic.201000456
- Kim B-G, Sung SH, Chong Y, Lim Y, Ahn J-H (2010) Plant flavonoid *O*-methyltransferases: substrate specificity and application. *J Plant Biol* 53(5):321–329. doi:10.1007/s12374-010-9126-7



14. Kim BG, Kim HJ, Ahn J-H (2012) Production of bioactive flavonol rhamnosides by expression of plant genes in *Escherichia coli*. J Agr Food Chem 60(44):11143–11148. doi:10.1021/jf302123c
15. Kim B-G, Sung SH, Ahn J-H (2012) Biological synthesis of quercetin 3-*O*-*N*-acetylglucosamine conjugate using engineered *Escherichia coli* expressing UGT78D2. Appl Microbiol Biotechnol 93(6):2447–2453. doi:10.1007/s00253-011-3747-8
16. Kim BG, Yang SM, Kim SY, Cha MN, Ahn J-H (2015) Biosynthesis and production of glycosylated flavonoids in *Escherichia coli*: current state and perspectives. Appl Microbiol Biotechnol 99(7):2979–2988. doi:10.1007/s00253-015-6504-6
17. Kim HS, Kim B-G, Sung S, Kim M, Mok H, Chong Y, Ahn J-H (2013) Engineering flavonoid glycosyltransferases for enhanced catalytic efficiency and extended sugar donor selectivity. Planta 238(4):683–693. doi:10.1007/s00425-013-1922-0
18. Kim SY, Lee HR, K-s Park, Kim BG, Ahn J-H (2015) Metabolic engineering of *Escherichia coli* for the biosynthesis of flavonoid *O*-glucuronides and flavonoid *O*-galactoside. Appl Microbiol Biotechnol 99(5):2233–2242. doi:10.1007/s00253-014-6282-6
19. Ko JH, Kim BG, Ahn J-H (2006) Glycosylation of flavonoids with a glycosyltransferase from *Bacillus cereus*. FEMS Microbiol Lett 258(2):263–268. doi:10.1111/j.1574-6968.2006.00226.x
20. La Casa C, Villegas I, Alarcón de la Lastra C, Motilva V, Martín Calero MJ (2000) Evidence for protective and antioxidant properties of rutin, a natural flavone, against ethanol induced gastric lesions. J Ethnopharmacol 71(1–2):45–53. doi:10.1016/S0378-8741(99)00174-9
21. Lee YS, Lee S, Lee HS, Kim BK, Ohuchi K, Shin KH (2005) Inhibitory effects of isorhamnetin-3-*O*-beta-D-glucoside from *Salicornia herbacea* on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. Biol Pharm Bull 28(5):916–918. doi:10.1248/bpb.28.916
22. Lim E-K, Ashford DA, Hou B, Jackson RG, Bowles DJ (2004) *Arabidopsis* glycosyltransferases as biocatalysts in fermentation for regioselective synthesis of diverse quercetin glucosides. Biotechnol Bioeng 87(5):623–631. doi:10.1002/bit.20154
23. Pandey RP, Malla S, Simkhada B, Kim B-G, Sohng JG (2013) Production of 3-*O*-xylosyl quercetin in *Escherichia coli*. Appl Microbiol Biotechnol 97(5):1889–1901. doi:10.1007/s00253-012-4438-9
24. Rodas FR, Rodriguez TO, Mura Y, Iwashina T, Sufawara S, Suzuki M, Nakabayashi R, Yonekura-Sakakibara Saito K, Kitajima J, Toda K, Takahashi R (2014) Linkage mapping, molecular cloning and functional analysis of soybean *Fg2* encoding flavonol 3-*O*-glucose (1→6) rhamnosyltransferase. Plant Mol Biol 84(3):287–300. doi:10.1007/s11103-013-0133-1
25. Sheu JR, Hsiao G, Chou PH, Shen MY, Chou DS (2004) Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem 52(14):4414–4418. doi:10.1021/jf040059f
26. Shui G, Peng LL (2004) An improved method for the analysis of major antioxidants of *Hibiscus esculentus* Linn. J Chromatogr A 1048(1):17–24. doi:10.1016/j.chroma.2004.07.032
27. Simkhada D, Lee HC, Sohng JK (2010) Genetic engineering approach for the production of rhamnosyl and allosyl flavonoids from *Escherichia coli*. Biotechnol Bioeng 107(1):154–162. doi:10.1002/bit.22782
28. Soundararajan R, Wishart AD, Rupasinghe HP, Arcellana-Panlilio M, Nelson CM, Mayne M, Robertson GS (2008) Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells in vitro against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. J Biol Chem 283(4):2231–2245. doi:10.1074/jbc.M703583200
29. Vogt T, Jones P (2000) Glycosyltransferases in plant natural product synthesis: characterization of a supergene family. Trend Plant Sci 5(9):380–386. doi:10.1016/S1360-1385(00)01720-9
30. Yonekura-Sakakibara K, Fukushima A, Nakabayashi R, Hanada K, Matsuda F, Sugawara S, Inoue E, Kuromori T, Ito T, Shinozaki K, Wangwattana B, Yamazaki M, Saito K (2012) Two glycosyltransferases involved in anthocyanin modification delineated by transcriptome independent component analysis in *Arabidopsis thaliana*. Plant J 69(1):154–167. doi:10.1111/j.1365-313X.2011.04779.x
31. Yonekura-Sakakibara K, Tohge T, Matsuda F, Nakabayashi R, Takayama H, Niida R, Watanabe-Takahashi A, Inoue E, Saito K (2008) Comprehensive flavonol profiling and transcriptome coexpression analysis leading to decoding gene-metabolite correlation in *Arabidopsis*. Plant Cell 20(8):2160–2176. doi:10.1105/tpc.108.058040
32. Yonekura-Sakakibara K, Hanada K (2011) An evolutionary view of functional diversity in family 1 glycosyltransferases. Plant J 66(1):182–193. doi:10.1111/j.1365-313X.2011.04493.x
33. Yoon J-A, Kim B-G, Lee WJ, Lim Y, Chong Y, Ahn J-H (2012) Production of a novel quercetin glycoside through metabolic engineering of *Escherichia coli*. Appl Env Microbiol 78(12):4256–4262. doi:10.1128/AEM.00275-12